Literature DB >> 9423140

Influence of race or ethnicity on pharmacokinetics of drugs.

J A Johnson1.   

Abstract

Review of the current literature on racial differences in pharmacokinetics of drugs supports the premise that only pharmacokinetic processes which are biologically or biochemically mediated have the potential to exhibit differences between racial or ethnic groups. Thus, the pharmacokinetic factors which can be expected to potentially exhibit racial differences are (1) bioavailability for drugs which undergo gut or hepatic first-pass metabolism, (2) protein binding, (3) volume of distribution, (4) hepatic metabolism, and (5) renal tubular secretion. Absorption (unless active), filtration at the glomerulus, and passive tubular reabsorption would not be expected to exhibit racial differences. As is evident from this review, there are relatively few drugs for which there is information on ethnic or racial differences in pharmacokinetics. Thus it is often necessary to try to predict whether such differences might exist. Taking into consideration the above factors and evaluation of the pharmacokinetic characteristics of the drug, it should be possible to identify those drugs most likely to exhibit differences in their pharmacokinetics. For example, a drug which is eliminated entirely by the kidneys through filtration and reabsorption and is not highly bound to plasma proteins (or is bound to albumin) is highly unlikely to exhibit racial differences in its kinetics. Conversely, a drug which undergoes significant gut and/or hepatic first-pass metabolism and is highly bound to AGP is much more likely to exhibit kinetic differences between racial groups. A discussion of the impact of racial differences in kinetics on drug response or racial differences in drug efficacy, toxicity, or pharmacodynamics (concentration-response relationship) is beyond the scope of this review. However, a number of the papers described above also evaluated differences in pharmacodynamics or response. Among the comparisons of Chinese and Caucasians, these include the papers on propranolol, morphine, nifedipine, triazolam, diazepam, and omeprazole. For those studies comparing differences in blacks and Caucasians, responses or pharmacodynamics were also determined in the studies of propranolol, trimazosin, and methylprednisolone. Interested readers are also referred to the review by Wood and a more recent review by Kitler for additional discussion of ethnic/racial differences in pharmacodynamics/drug response.

Entities:  

Mesh:

Year:  1997        PMID: 9423140     DOI: 10.1021/js9702168

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  43 in total

1.  In vivo effect of alpha(1)-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor.

Authors:  B M Sadler; C Gillotin; Y Lou; D S Stein
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

Review 2.  Recommendations of the clinical trials consensus panel. National Medical Association.

Authors: 
Journal:  J Natl Med Assoc       Date:  2000-10       Impact factor: 1.798

Review 3.  Evidence based medicine and justice: a framework for looking at the impact of EBM upon vulnerable or disadvantaged groups.

Authors:  W A Rogers
Journal:  J Med Ethics       Date:  2004-04       Impact factor: 2.903

4.  Should research samples reflect the diversity of the population?

Authors:  P Allmark
Journal:  J Med Ethics       Date:  2004-04       Impact factor: 2.903

5.  Statistical issues in a modeling approach to assessing bioequivalence or PK similarity with presence of sparsely sampled subjects.

Authors:  Chuanpu Hu; Katy H P Moore; Yong H Kim; Mark E Sale
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-08       Impact factor: 2.745

Review 6.  Safety and efficacy of statins in Asians.

Authors:  James K Liao
Journal:  Am J Cardiol       Date:  2006-12-15       Impact factor: 2.778

Review 7.  Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics.

Authors:  Mei-Ling Chen
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

8.  Population pharmacokinetic/pharmacodynamic modelling of eltrombopag in healthy volunteers and subjects with chronic liver disease.

Authors:  Colm Farrell; Siobhan C Hayes; Mary Wire; Jianping Zhang
Journal:  Br J Clin Pharmacol       Date:  2014-03       Impact factor: 4.335

9.  Impact of Demographics, Organ Impairment, Disease, Formulation, and Food on the Pharmacokinetics of the Selective S1P1 Receptor Modulator Ponesimod Based on 13 Clinical Studies.

Authors:  Dominik Lott; Thorsten Lehr; Jasper Dingemanse; Andreas Krause
Journal:  Clin Pharmacokinet       Date:  2017-04       Impact factor: 6.447

10.  Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine.

Authors:  Melton Affrime; Christopher Banfield; Samir Gupta; Albert Cohen; Tanya Boutros; Mohan Thonoor; Mitchell Cayen
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.